Results 141 to 150 of about 464,004 (267)

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension. [PDF]

Pediatr Pulmonol
Tsoi SM, Parker C, Colglazier E, Cheung S, Taleb M, Nawaytou H, Amin E, Fineman JR, Keller RL.   +8 more
europepmc   +1 more source

Pathophysiology and Diagnosis of Pulmonary Hypertension Due to Left Heart Disease [PDF]

, 2018
Athanasios Charalampopoulos, Robert A. Lewis, Peter Hickey, Charlotte Durrington, Charlie Elliot, Robin Condliffe, Ian Sabroe, David G. Kiely   +7 more
openalex   +1 more source

Phenotyping vasodilator responsiveness in idiopathic pulmonary arterial hypertension: any role for the cardiopulmonary exercise test?

ERJ Open Research
Gayathiri Sivasubramaniam, Andrea Baccelli, Gulam Haji, Francesco Lo Giudice, Clare Weaver, Luke Howard, Rachel Davies   +6 more
doaj   +1 more source

Lung transplantation for chronic thromboembolic pulmonary hypertension. [PDF]

JHLT Open
Godinas L, Orlitová M, Muscogiuri E, Ceulemans L, Fadel E, Delcroix M, Verbelen T.   +6 more
europepmc   +1 more source

Bradycardia-Associated Pulmonary Hypertension. [PDF]

JACC Case Rep
Long Y, Li W, Bai Y, Zhou D, Pan W, Ge J.   +5 more
europepmc   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis–Associated Interstitial Lung Disease: An Emulated Target Trial

Arthritis &Rheumatology, EarlyView.
Objective The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA‐ILD.
Po‐Cheng Shih, Shiow‐Ing Wang, Qing‐Wen Wang, James Cheng Chung Wei   +3 more
wiley   +1 more source

Multidimensional study on mitochondrial dysfunction in pulmonary hypertension. [PDF]

Front Med (Lausanne)
Yuan X, Zhang Y, Liu Y, Guo X, Jia S, Xiong X, Sun X, Jin Z.   +7 more
europepmc   +1 more source

Reactive Oxygen Species–Induced Modifications of Fibrin Clots as a Link Between Immune Responses and Atherothrombosis in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Cardiovascular events are major determinants of morbidity and mortality in systemic lupus erythematosus (SLE), particularly in patients with renal involvement. Although oxidative stress has been implicated in driving vascular and renal damage in SLE, the specific mechanisms remain unclear.
Matteo Becatti, Giacomo Emmi, Alessandra Bettiol, Amanda Mannucci, Flavia Rita Argento, Eleonora Fini, Serena Borghi, Francesca Nencini, Maria Nicastro, Irene Mattioli, Elena Silvestri, Augusto Vaglio, Domenico Prisco, Claudia Fiorillo   +13 more
wiley   +1 more source